De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy

J Am Acad Dermatol. 2024 Oct;91(4):720-722. doi: 10.1016/j.jaad.2024.05.068. Epub 2024 Jun 4.
No abstract available

Keywords: belatacept; nonmelanoma skin cancer; renal transplant recipient; skin cancer; transplant dermatology.

Publication types

  • Letter
  • Comparative Study

MeSH terms

  • Abatacept* / therapeutic use
  • Adult
  • Aged
  • Female
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents* / adverse effects
  • Immunosuppressive Agents* / therapeutic use
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Retrospective Studies
  • Skin Neoplasms* / drug therapy

Substances

  • Abatacept
  • Immunosuppressive Agents